StockWatch
·
Q2 FY-2027 RESULTS · SBILIFE

SBI Life Q2 FY27 standalone PAT ₹549 Cr, +11% YoY but below Street view; margins compress

PAT +11.05% YoY · revenue +13.19% · margins compressing · miss vs street

Q2 FY27 resultsSBILIFESBI Life Insurance Company Ltd27 Oct 2026 · 3 min read
Revenue

₹597.5 Cr

+13.19% YoY

PAT (standalone)

₹549.23 Cr

+11.05% YoY

Net margin

91.89%

-1.8pp YoY

EPS

₹5.47

SBI Life's standalone PAT for Q2 FY27 came in at ₹549.23 Cr, up 11.1% YoY from ₹494.59 Cr a year ago but down 24.2% sequentially from Q1 FY27's ₹724.93 Cr. That YoY growth, while positive, lands well short of the ~₹700-750 Cr Street consensus flagged in our pre-result preview — a miss of roughly a fifth to a quarter against the range 35 covering analysts were pricing in. Shareholders' account revenue (investment income plus transfer from the policyholders' account) was ₹597.71 Cr, up 13.2% YoY but down 19.2% QoQ. Basic EPS was ₹5.47 for the quarter (H1 FY27 EPS ₹12.70), versus ₹7.23 in Q1 FY27 and ₹4.93 a year ago.

The scoreboard

Q2 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹597.5 Cr-19.2%+13.2%
Expenses₹43.99 Cr+793%+195.8%
PAT₹549.23 Cr-24.23%+11.05%
Net margin91.89%-6.1pp-1.8pp
EPS₹5.47-24.3%+11%

Net margin compressed to 91.9% of shareholders' revenue from 98.0% in Q1 FY27 and 93.7% in Q2 FY26. The swing traces to the shareholders' account bridge: a ₹31.0 Cr provision for diminution in investment value this quarter versus a ₹13.3 Cr write-back in Q1 FY27 (a ~₹44 Cr adverse turn), plus a smaller transfer from the policyholders' account (₹241.67 Cr versus ₹457.78 Cr in Q1). Underlying insurance growth was healthier than the profit line suggests: net premium income rose 8.2% YoY to ₹26,877.70 Cr, but new business premium (first year plus single premium) grew just 2.4% YoY to ₹11,351.49 Cr — a softer pace than the 14-15% full-year individual rated premium growth management reiterated on the Q1 FY27 call, and the direct answer to the 'growth test' watch item we flagged pre-result.

₹
1,599.161,686.581,7741,861.421,948.841,63307-2408-1709-0810-0110-27Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,633, down 7% over the past month of trading.

₹ Cr
0300.4600.8901.2594.37Q1 FY26rev ₹614 Cr494.59Q2 FY26rev ₹528 Cr576.74Q3 FY26rev ₹626 Cr804.64Q4 FY26rev ₹2,690 Cr724.93Q1 FY27rev ₹740 Cr
Quarterly standalone PAT, ₹ Crore
Beyond the headline

What the summary numbers don't show

No consolidated results — company confirms it has no subsidiary/associate/JV requiring consolidation

What management guided (1 FY-2027 call)
FY27 IRP growth 14–15% (maintained from prior guidance). VoNB margin 26–28% range (maintained but at lower end; management expects recovery to upper range as product mix normalizes and GTI lumpiness subsides). Deferred annuity launch moved to Q2 FY27 (missed Q1 deadline).

The Street went into this print expecting SBI Life to defend its 26-28% VNB margin and sustain the 22% YoY profit growth it posted in Q1; FY27 consensus had pegged EPS at ₹29.45 (+19.6% YoY), a run-rate this quarter's ₹5.47 falls short of absent a much stronger H2. This filing, however, does not disclose VNB margin or APE for the quarter — those come in the company's separate investor presentation — so the 'profitability test' watch item from our preview cannot be graded from the statement alone; what the filing does carry is an independent WTW actuarial opinion valuing embedded value at ₹87,350 Cr as at September 30, 2026, with H1 FY27 value of new business at ₹3,270 Cr. Solvency stayed comfortable at 1.97x (versus 1.94x a year ago). None of the quarter's other corporate developments — the ₹1.13 Cr GST demand company plans to appeal, Nihar Jambusaria's appointment as additional independent director, or the joint statutory auditor reappointment — are financially material to the print. No separate management press release was available in our records to cross-check against the numbers.

  • W1

    Margin recovery: NPM was 91.9% this quarter versus 98.0% in Q1 FY27 — watch whether the ₹31.0 Cr investment-diminution provision reverses in H2

  • W2

    New business premium growth ran at just 2.4% YoY (₹11,351 Cr) versus management's 14-15% FY27 IRP growth guidance — needs to accelerate

  • W3

    VNB margin for Q2 FY27 (not disclosed in this filing) — confirm it held the 26-28% range management reiterated on the Q1 FY27 call

Insurer format: figures are the Shareholders' A/c P&L (transfer from Policyholders' A/c + investment/other income minus expenses/provisions), the basis that drives reported PAT and EPS; source is in ₹ Lakh, divided by 100 for ₹ Cr. No consolidated statement — Note 1 states the company has no subsidiary/associate/JV requiring consolidation under AS-21. Unaudited, limited-review only (K S Aiyar & Co and J Singh & Associates, unmodified opinion).

Informational and educational content only. Not investment advice.